Role of apoptosis in the intestinal epithelium during homeostasis and disease

肠上皮细胞凋亡在稳态和疾病过程中的作用

基本信息

项目摘要

PROPOSAL SUMMARY The intestinal epithelium protects against food antigens and the luminal microbiota by forming a physical barrier and actively secreting mucous and anti-microbial peptides. The intestinal epithelium is maintained by a process of constant renewal through a cycle of cell division, differentiation, and apoptosis. Apoptosis is a potent inducer of regulatory CD4 T (TREG) cells and immune tolerance. During infection, apoptosis induces a tailored CD4 T helper 17 (TH17) response. Whether apoptosis of intestinal epithelial cells (IEC) plays any role in intestinal tolerance and effector response is not known. Professional mononuclear phagocytes (MP), such as macrophages and dendritic cells (DC), clear microbial pathogens during infection and apoptotic cells during embryonic development and tissue remodeling. While much attention has centered on MP sampling of commensal and pathogenic microorganisms within the gut lumen, less attention is directed towards sampling of apoptotic IEC, despite the prominent role that apoptosis plays in the intestinal epithelium. Interference with the natural cycle of apoptosis in IEC leads to intestinal inflammation in mouse models. There is increased IEC death and damage to the intestinal epithelium in patients with inflammatory bowel disease (IBD), and this fuels intestinal dybsiosis and inflammation. Several international IBD genome wide association studies (GWAS) and meta-analyses have associated susceptibility to IBD with genes involved in pathways regulating innate immune responses, immunomodulatory cytokines, and TH17 signaling. Gene expression data from different murine cell types have shown the strongest enrichment of IBD genes in innate immune cells, particularly DC. Gaining an understanding of whether and how apoptosis of the intestinal epithelium impacts the processes of tolerance and immunity within the intestine is therefore of utmost importance. Using two novel mouse models, we will determine how increasing or impairing apoptosis of the intestinal epithelium impacts the homeostatic and immune responses within the intestine. We have compelling evidence that apoptosis in the small intestinal epithelium is not a bystander event, but actively imprints lamina propria MP with `suppression of inflammation' and `induction of TREG cell' transcriptional signatures. Notably, many of the genes differentially modulated in MP after apoptotic IEC uptake overlap with IBD genes. Here we will examine the identities and profiles of colonic MP during steady state and infection. We will investigate how apoptosis impacts the functions of intestinal MP as they relate to various mechanisms of immune tolerance and effector response in the intestine. This includes their response to microbial components, their maintenance of innate lymphoid cells, and their instruction of TREG and TH17 cell fates. All these parameters are disrupted in IBD. By the completion of these studies, we will have gained new insights into the role of apoptosis in intestinal immune regulation, advance our understanding of how homeostasis is maintained within the mucosa, and set the stage for development of novel therapeutics for inflammatory diseases such as IBD.
提案摘要 肠上皮通过形成物理结构来防御食物抗原和肠腔微生物群。 屏障并积极分泌粘液和抗微生物肽。肠上皮由以下物质维持 通过细胞分裂、分化和凋亡循环不断更新的过程。细胞凋亡是一种 调节性 CD4 T (TREG) 细胞和免疫耐受的有效诱导剂。在感染过程中,细胞凋亡会诱导 定制的 CD4 T 辅助细胞 17 (TH17) 反应。肠上皮细胞凋亡(IEC)是否发挥作用 肠道耐受性和效应反应尚不清楚。专业单核吞噬细胞(MP),例如 作为巨噬细胞和树突状细胞(DC),在感染过程中清除微生物病原体,在感染过程中清除凋亡细胞 胚胎发育和组织重塑。虽然很多注意力都集中在 MP 采样上 肠腔内的共生微生物和病原微生物,较少关注采样 尽管细胞凋亡在肠上皮细胞中发挥着重要作用,但细胞凋亡的 IEC 仍然存在。干扰 IEC 中细胞凋亡的自然循环会导致小鼠模型肠道炎症。 IEC 增加 炎症性肠病(IBD)患者的死亡和肠上皮损伤,这加剧了 肠道菌群失调和炎症。多项国际 IBD 全基因组关联研究 (GWAS) 和 荟萃分析将 IBD 易感性与调节先天免疫途径的基因相关联 反应、免疫调节细胞因子和 TH17 信号传导。来自不同小鼠细胞的基因表达数据 类型显示出先天免疫细胞(尤其是 DC)中 IBD 基因的最强富集。获得 了解肠上皮细胞凋亡是否以及如何影响耐受过程 因此,肠道内的免疫力至关重要。 使用两种新的小鼠模型,我们将确定如何增加或削弱细胞凋亡 肠上皮影响肠道内的稳态和免疫反应。我们有令人信服的 有证据表明小肠上皮细胞凋亡不是旁观者事件,而是主动印记层 propria MP 具有“抑制炎症”和“诱导 TREG 细胞”转录特征。尤其, 凋亡性 IEC 摄取后 MP 中差异调节的许多基因与 IBD 基因重叠。在这里我们 将检查稳态和感染期间结肠 MP 的身份和概况。我们将调查如何 细胞凋亡影响肠道 MP 的功能,因为它们与多种免疫耐受机制有关 和肠道内的效应器反应。这包括它们对微生物成分的反应、它们的维护 先天淋巴细胞的结构,及其对 TREG 和 TH17 细胞命运的指导。所有这些参数都被打乱 炎症性肠病。通过完成这些研究,我们将对细胞凋亡在肠道中的作用有新的认识。 免疫调节,增进我们对如何维持粘膜内稳态的理解,并设定 IBD 等炎症性疾病新疗法的开发阶段。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Julie Magarian Blander其他文献

Julie Magarian Blander的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Julie Magarian Blander', 18)}}的其他基金

Mobilizing TAP-independent CD8 T cells through non-canonical cross-presentation
通过非规范交叉呈递动员不依赖 TAP 的 CD8 T 细胞
  • 批准号:
    10659785
  • 财政年份:
    2023
  • 资助金额:
    $ 38.14万
  • 项目类别:
Modulating XIAP for the Treatment of Inflammatory Bowel Disease
调节 XIAP 治疗炎症性肠病
  • 批准号:
    10727185
  • 财政年份:
    2023
  • 资助金额:
    $ 38.14万
  • 项目类别:
Toll-like receptor control of endocytic antigen cross-presentation
Toll 样受体控制内吞抗原交叉呈递
  • 批准号:
    10735354
  • 财政年份:
    2023
  • 资助金额:
    $ 38.14万
  • 项目类别:
Toll-like Receptor Control of MHC Class I Endocytosis
MHC I 类内吞作用的 Toll 样受体控制
  • 批准号:
    10453097
  • 财政年份:
    2022
  • 资助金额:
    $ 38.14万
  • 项目类别:
Toll-like Receptor Control of MHC Class I Endocytosis
MHC I 类内吞作用的 Toll 样受体控制
  • 批准号:
    10557150
  • 财政年份:
    2022
  • 资助金额:
    $ 38.14万
  • 项目类别:
Innate and Adaptive Immune Consequences of Necroptosis
坏死性凋亡的先天性和适应性免疫后果
  • 批准号:
    10196978
  • 财政年份:
    2020
  • 资助金额:
    $ 38.14万
  • 项目类别:
Innate and Adaptive Immune Consequences of Necroptosis
坏死性凋亡的先天性和适应性免疫后果
  • 批准号:
    10043494
  • 财政年份:
    2020
  • 资助金额:
    $ 38.14万
  • 项目类别:
Non-Canonical Cross-presentation in Dendritic Cells Upon TAP Blockade
TAP 阻断后树突状细胞中的非典型交叉呈递
  • 批准号:
    9404238
  • 财政年份:
    2017
  • 资助金额:
    $ 38.14万
  • 项目类别:
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccines
新型维生素疫苗配方结合了死疫苗的安全性和活疫苗的功效
  • 批准号:
    9357501
  • 财政年份:
    2016
  • 资助金额:
    $ 38.14万
  • 项目类别:
Control of protective immunity by innate pathways sensing bacterial viability
通过感知细菌活力的先天途径控制保护性免疫
  • 批准号:
    8528462
  • 财政年份:
    2012
  • 资助金额:
    $ 38.14万
  • 项目类别:

相似国自然基金

巨噬细胞Nogo-B通过FABP4/IL-18/IL-18R调控急性肝衰竭的分子机制研究
  • 批准号:
    82304503
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于解郁散热“把好气分关”探讨代谢-炎症“开关”A2BR在急性胰腺炎既病防变中的作用与机制
  • 批准号:
    82374256
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
RacGAP1介导细胞核-线粒体对话在急性肾损伤中促进肾小管上皮细胞能量平衡的作用机制研究
  • 批准号:
    82300771
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
开窍寒温配伍调控应激颗粒铁离子富集水平抗急性缺血性卒中铁死亡损伤的机制研究
  • 批准号:
    82374209
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目

相似海外基金

Pharmacologic Inhibition of NLRP3 Inflammasome-Dependent Injury following Vaso-occlusion in Sickle Cell Disease
镰状细胞病血管闭塞后 NLRP3 炎症小体依赖性损伤的药理学抑制
  • 批准号:
    10258844
  • 财政年份:
    2021
  • 资助金额:
    $ 38.14万
  • 项目类别:
Generation of Endothelial Cell Memory in Inflammatory Vascular Disease
炎症性血管疾病中内皮细胞记忆的产生
  • 批准号:
    10282954
  • 财政年份:
    2021
  • 资助金额:
    $ 38.14万
  • 项目类别:
Generation of Endothelial Cell Memory in Inflammatory Vascular Disease
炎症性血管疾病中内皮细胞记忆的产生
  • 批准号:
    10671561
  • 财政年份:
    2021
  • 资助金额:
    $ 38.14万
  • 项目类别:
Hyperglycemia mediated myeloproliferative disease
高血糖介导的骨髓增生性疾病
  • 批准号:
    10386813
  • 财政年份:
    2019
  • 资助金额:
    $ 38.14万
  • 项目类别:
Hyperglycemia mediated myeloproliferative disease
高血糖介导的骨髓增生性疾病
  • 批准号:
    9899320
  • 财政年份:
    2019
  • 资助金额:
    $ 38.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了